Insight Molecular Diagnostics (IMDX) Equity Average: 2020-2025
Historic Equity Average for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Sep 2025 value amounting to -$4.0 million.
- Insight Molecular Diagnostics' Equity Average fell 124.98% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.0 million, marking a year-over-year decrease of 124.98%. This contributed to the annual value of $4.1 million for FY2024, which is 85.04% down from last year.
- Per Insight Molecular Diagnostics' latest filing, its Equity Average stood at -$4.0 million for Q3 2025, which was down 171.56% from $5.7 million recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Equity Average registered a high of $104.6 million during Q2 2021, and its lowest value of -$4.0 million during Q3 2025.
- For the 3-year period, Insight Molecular Diagnostics' Equity Average averaged around $13.1 million, with its median value being $16.0 million (2024).
- In the last 5 years, Insight Molecular Diagnostics' Equity Average soared by 174.60% in 2021 and then crashed by 124.98% in 2025.
- Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Equity Average stood at $82.3 million in 2021, then slumped by 32.46% to $55.6 million in 2022, then plummeted by 47.79% to $29.0 million in 2023, then crashed by 104.42% to -$1.3 million in 2024, then slumped by 124.98% to -$4.0 million in 2025.
- Its Equity Average stands at -$4.0 million for Q3 2025, versus $5.7 million for Q2 2025 and -$1.0 million for Q1 2025.